,Pharmacotherapeutics Ifor IAdvanced IPractice INurse IPrescribers I6th IEdition IWoo IRobinson ITest IBank
Chapter I1. IThe IRole Iof Ithe INurse
IPractitioner IMultiple IChoice
Identify Ithe Ichoice Ithat Ibest Icompletes Ithe Istatement Ior Ianswers Ithe Iquestion.
I 1. INurse Ipractitioner Iprescriptive Iauthority Iis Iregulated I by:
1. The INational ICouncil Iof IState IBoards Iof INursing
2. The IU.S. IDrug IEnforcement IAdministration
3. The IState IBoard Iof INursing Ifor Ieach Istate
4. The IState IBoard Iof IPharmacy
I 2. IThe Ibenefits Ito Ithe Ipatient Iof Ihaving Ian IAdvanced IPractice IRegistered INurse I(APRN)
Iprescriber Iinclude:
1. Nurses Iknow Imore Iabout IPharmacology Ithan Iother Iprescribers Ibecause Ithey
Itake Iit Iboth Iin Itheir Ibasic Inursing Iprogram Iand Iin Itheir IAPRN Iprogram.
2. Nurses Icare Ifor Ithe Ipatient Ifrom Ia Iholistic Iapproach Iand Iinclude Ithe
Ipatient Iin Idecision Imaking Iregarding Itheir Icare.
3. APRNs Iare Iless Ilikely Ito Iprescribe Inarcotics Iand Iother Icontrolled Isubstances.
4. APRNs Iare Iable Ito Iprescribe Iindependently Iin Iall Istates, Iwhereas Ia
Iphysician’s Iassistant Ineeds Ito Ihave Ia Iphysician Isupervising Itheir Ipractice.
I 3. IClinical Ijudgment Iin Iprescribing I includes:
1. Factoring Iin Ithe Icost Ito Ithe Ipatient Iof Ithe Imedication Iprescribed
2. Always Iprescribing Ithe Inewest Imedication Iavailable Ifor Ithe Idisease Iprocess
3. Handing Iout Idrug Isamples Ito Ipoor Ipatients
4. Prescribing Iall Igeneric Imedications Ito Icut Icosts
I 4. ICriteria Ifor Ichoosing Ian Ieffective Idrug Ifor Ia Idisorder I include:
1. Asking Ithe Ipatient Iwhat Idrug Ithey Ithink Iwould Iwork Ibest Ifor Ithem
2. Consulting Inationally Irecognized Iguidelines Ifor Idisease Imanagement
3. Prescribing Imedications Ithat Iare Iavailable Ias Isamples Ibefore Iwriting Ia Iprescription
4. Following IU.S. IDrug IEnforcement IAdministration Iguidelines Ifor Iprescribing
I 5. INurse Ipractitioner Ipractice Imay Ithrive Iunder Ihealth-care Ireform Ibecause I of:
1. The Idemonstrated Iability Iof Inurse Ipractitioners Ito Icontrol Icosts Iand Iimprove
Ipatient Ioutcomes
2. The Ifact Ithat Inurse Ipractitioners Iwill Ibe Iable Ito Ipractice Iindependently
3. The Ifact Ithat Inurse Ipractitioners Iwill Ihave Ifull Ireimbursement Iunder Ihealth-
care Ireform
4. The Iability Ito Ishift Iaccountability Ifor IMedicaid Ito Ithe Istate Ilevel
,
, Chapter I1. IThe IRole Iof Ithe INurse
IPractitioner IAnswer ISection
MULTIPLE ICHOICE
1. ANS: I I3 PTS: I 1
2. ANS: I I2 PTS: I 1
3. ANS: I I1 PTS: I 1
4. ANS: I I2 PTS: I 1
5. ANS: I I1 PTS: I 1
Chapter I2. IReview Iof IBasic IPrinciples Iof IPharmacology
IMultiple IChoice
Identify Ithe Ichoice Ithat Ibest Icompletes Ithe Istatement Ior Ianswers Ithe Iquestion.
I 1. IA Ipatient’s Inutritional Iintake Iand Ilaboratory Iresults Ireflect Ihypoalbuminemia. IThis Iis
Icritical Ito Iprescribing Ibecause:
1. Distribution Iof Idrugs Ito Itarget Itissue Imay Ibe Iaffected.
2. The Isolubility Iof Ithe Idrug Iwill Inot Imatch Ithe Isite Iof Iabsorption.
3. There Iwill Ibe Iless Ifree Idrug Iavailable Ito Igenerate Ian Ieffect.
4. Drugs Ibound Ito Ialbumin Iare Ireadily Iexcreted Iby Ithe Ikidneys.
I 2. IDrugs Ithat Ihave Ia Isignificant Ifirst-pass I effect:
1. Must Ibe Igiven Iby Ithe Ienteral I(oral) Iroute Ionly
2. Bypass Ithe Ihepatic Icirculation
3. Are Irapidly Imetabolized Iby Ithe Iliver Iand Imay Ihave Ilittle Iif Iany Idesired Iaction
4. Are Iconverted Iby Ithe Iliver Ito Imore Iactive Iand Ifat-soluble Iforms
I I 3. IThe Iroute Iof Iexcretion Iof Ia Ivolatile Idrug Iwill Ilikely Ibe I the:
1. Kidneys
2. Lungs
3. Bile Iand Ifeces
4. Skin
I 4. IMedroxyprogesterone I(Depo IProvera) Iis Iprescribed Iintramuscularly I(IM) Ito Icreate Ia
Istorage Ireservoir Iof Ithe Idrug. IStorage Ireservoirs:
1. Assure Ithat Ithe Idrug Iwill Ireach Iits Iintended Itarget Itissue
2. Are Ithe Ireason Ifor Igiving Iloading Idoses
3. Increase Ithe Ilength Iof Itime Ia Idrug Iis Iavailable Iand Iactive
4. Are Imost Icommon Iin Icollagen Itissues
I I 5. IThe INP Ichooses Ito Igive Icephalexin Ievery I8 Ihours Ibased Ion Iknowledge Iof Ithe I drug’s:
1. Propensity Ito Igo Ito Ithe Itarget Ireceptor
2. Biological Ihalf-life
3. Pharmacodynamics
4. Safety Iand Iside Ieffects
Chapter I1. IThe IRole Iof Ithe INurse
IPractitioner IMultiple IChoice
Identify Ithe Ichoice Ithat Ibest Icompletes Ithe Istatement Ior Ianswers Ithe Iquestion.
I 1. INurse Ipractitioner Iprescriptive Iauthority Iis Iregulated I by:
1. The INational ICouncil Iof IState IBoards Iof INursing
2. The IU.S. IDrug IEnforcement IAdministration
3. The IState IBoard Iof INursing Ifor Ieach Istate
4. The IState IBoard Iof IPharmacy
I 2. IThe Ibenefits Ito Ithe Ipatient Iof Ihaving Ian IAdvanced IPractice IRegistered INurse I(APRN)
Iprescriber Iinclude:
1. Nurses Iknow Imore Iabout IPharmacology Ithan Iother Iprescribers Ibecause Ithey
Itake Iit Iboth Iin Itheir Ibasic Inursing Iprogram Iand Iin Itheir IAPRN Iprogram.
2. Nurses Icare Ifor Ithe Ipatient Ifrom Ia Iholistic Iapproach Iand Iinclude Ithe
Ipatient Iin Idecision Imaking Iregarding Itheir Icare.
3. APRNs Iare Iless Ilikely Ito Iprescribe Inarcotics Iand Iother Icontrolled Isubstances.
4. APRNs Iare Iable Ito Iprescribe Iindependently Iin Iall Istates, Iwhereas Ia
Iphysician’s Iassistant Ineeds Ito Ihave Ia Iphysician Isupervising Itheir Ipractice.
I 3. IClinical Ijudgment Iin Iprescribing I includes:
1. Factoring Iin Ithe Icost Ito Ithe Ipatient Iof Ithe Imedication Iprescribed
2. Always Iprescribing Ithe Inewest Imedication Iavailable Ifor Ithe Idisease Iprocess
3. Handing Iout Idrug Isamples Ito Ipoor Ipatients
4. Prescribing Iall Igeneric Imedications Ito Icut Icosts
I 4. ICriteria Ifor Ichoosing Ian Ieffective Idrug Ifor Ia Idisorder I include:
1. Asking Ithe Ipatient Iwhat Idrug Ithey Ithink Iwould Iwork Ibest Ifor Ithem
2. Consulting Inationally Irecognized Iguidelines Ifor Idisease Imanagement
3. Prescribing Imedications Ithat Iare Iavailable Ias Isamples Ibefore Iwriting Ia Iprescription
4. Following IU.S. IDrug IEnforcement IAdministration Iguidelines Ifor Iprescribing
I 5. INurse Ipractitioner Ipractice Imay Ithrive Iunder Ihealth-care Ireform Ibecause I of:
1. The Idemonstrated Iability Iof Inurse Ipractitioners Ito Icontrol Icosts Iand Iimprove
Ipatient Ioutcomes
2. The Ifact Ithat Inurse Ipractitioners Iwill Ibe Iable Ito Ipractice Iindependently
3. The Ifact Ithat Inurse Ipractitioners Iwill Ihave Ifull Ireimbursement Iunder Ihealth-
care Ireform
4. The Iability Ito Ishift Iaccountability Ifor IMedicaid Ito Ithe Istate Ilevel
,
, Chapter I1. IThe IRole Iof Ithe INurse
IPractitioner IAnswer ISection
MULTIPLE ICHOICE
1. ANS: I I3 PTS: I 1
2. ANS: I I2 PTS: I 1
3. ANS: I I1 PTS: I 1
4. ANS: I I2 PTS: I 1
5. ANS: I I1 PTS: I 1
Chapter I2. IReview Iof IBasic IPrinciples Iof IPharmacology
IMultiple IChoice
Identify Ithe Ichoice Ithat Ibest Icompletes Ithe Istatement Ior Ianswers Ithe Iquestion.
I 1. IA Ipatient’s Inutritional Iintake Iand Ilaboratory Iresults Ireflect Ihypoalbuminemia. IThis Iis
Icritical Ito Iprescribing Ibecause:
1. Distribution Iof Idrugs Ito Itarget Itissue Imay Ibe Iaffected.
2. The Isolubility Iof Ithe Idrug Iwill Inot Imatch Ithe Isite Iof Iabsorption.
3. There Iwill Ibe Iless Ifree Idrug Iavailable Ito Igenerate Ian Ieffect.
4. Drugs Ibound Ito Ialbumin Iare Ireadily Iexcreted Iby Ithe Ikidneys.
I 2. IDrugs Ithat Ihave Ia Isignificant Ifirst-pass I effect:
1. Must Ibe Igiven Iby Ithe Ienteral I(oral) Iroute Ionly
2. Bypass Ithe Ihepatic Icirculation
3. Are Irapidly Imetabolized Iby Ithe Iliver Iand Imay Ihave Ilittle Iif Iany Idesired Iaction
4. Are Iconverted Iby Ithe Iliver Ito Imore Iactive Iand Ifat-soluble Iforms
I I 3. IThe Iroute Iof Iexcretion Iof Ia Ivolatile Idrug Iwill Ilikely Ibe I the:
1. Kidneys
2. Lungs
3. Bile Iand Ifeces
4. Skin
I 4. IMedroxyprogesterone I(Depo IProvera) Iis Iprescribed Iintramuscularly I(IM) Ito Icreate Ia
Istorage Ireservoir Iof Ithe Idrug. IStorage Ireservoirs:
1. Assure Ithat Ithe Idrug Iwill Ireach Iits Iintended Itarget Itissue
2. Are Ithe Ireason Ifor Igiving Iloading Idoses
3. Increase Ithe Ilength Iof Itime Ia Idrug Iis Iavailable Iand Iactive
4. Are Imost Icommon Iin Icollagen Itissues
I I 5. IThe INP Ichooses Ito Igive Icephalexin Ievery I8 Ihours Ibased Ion Iknowledge Iof Ithe I drug’s:
1. Propensity Ito Igo Ito Ithe Itarget Ireceptor
2. Biological Ihalf-life
3. Pharmacodynamics
4. Safety Iand Iside Ieffects
